The Subject Expert Committee (SEC) of the Central Drug Standards Control Organisation (CDSCO) is understood to have recommended Phase II and III clinical trials of Covaxin on children aged between 2 and 18 years.
Hyderabad-based maker of the vaccine, Bharat Biotech, had submitted a proposal in this regard and was asked to submit a revised clinical trial protocol.
clinical trials of Covaxin on children aged between 2 and 18 years
The company was also asked to submit the interim safety data of Phase II clinical trials along with the DSMB (Data and Safety Monitoring Board) recommendations to the CDSCO before proceeding to Phase III of the study, according to sources
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.